95 related articles for article (PubMed ID: 27842401)
1. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
Scheinberg M; Ferreira SB
Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
[No Abstract] [Full Text] [Related]
2. Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth.
Schwartzberg L; Spizuoco A
Cutis; 2023 Nov; 112(5):E5-E9. PubMed ID: 38091428
[TBL] [Abstract][Full Text] [Related]
3. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia.
Chen LC; Ogbutor C; Kelley KJ; Senna MM
J Am Acad Dermatol; 2024 Jun; 90(6):1260-1262. PubMed ID: 38311243
[No Abstract] [Full Text] [Related]
4. Pregnancy outcomes following tofacitinib use for synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: Case report.
Zhang C; Shi X; Ding Y; Lin Z; Qian T; Liu X; Hou X; Li C
Int J Rheum Dis; 2024 Jun; 27(6):e15209. PubMed ID: 38873853
[No Abstract] [Full Text] [Related]
5. Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib.
Castillo R; Albayda J
Mod Rheumatol Case Rep; 2022 Jun; 6(2):199-202. PubMed ID: 35253877
[TBL] [Abstract][Full Text] [Related]
6. Review of the use of Janus kinase inhibitors in the treatment of scarring alopecia.
Nohria A; Desai D; Shapiro J; Bordone L; Lo Sicco K
Int J Dermatol; 2024 Jun; 63(6):e105-e110. PubMed ID: 38571280
[No Abstract] [Full Text] [Related]
7. Generic Tofacitinib-A More Affordable JAK Inhibitor.
Goll GL; Kvien TK
Mayo Clin Proc; 2024 Jan; 99(1):4-6. PubMed ID: 38176834
[No Abstract] [Full Text] [Related]
8. Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data.
Boneschansker L; Ananthakrishnan AN;
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2427-2429.e1. PubMed ID: 37031712
[No Abstract] [Full Text] [Related]
9. Tofacitinib: a successful treatment option for SAPHO syndrome.
Sarikaya Solak S; Yelgen Ilyas H
Int J Dermatol; 2024 May; 63(5):671-674. PubMed ID: 38357788
[No Abstract] [Full Text] [Related]
10. Treatment of lichen planopilaris with Janus kinase inhibitors.
Gonzalez Matheus GA; Khosrotehrani K
Australas J Dermatol; 2024 Jun; 65(4):381-383. PubMed ID: 38421900
[No Abstract] [Full Text] [Related]
11. Tofacitinib treatment in a severe pediatric alopecia areata: A case report and a literature review.
Ma Y; Wang W; Shi D
Skin Res Technol; 2024 Jan; 30(1):e13553. PubMed ID: 38186061
[No Abstract] [Full Text] [Related]
12. Rapid and sustained improvement of cutaneous lichen planus with oral JAK1 inhibitors.
Böll SL; Zahn CA; Schlapbach C
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e82-e85. PubMed ID: 37595958
[No Abstract] [Full Text] [Related]
13. Janus kinase inhibitor Abrocitinib as an Off-Label treatment for tattoo granuloma with uveitis (TAGU).
Yang Y; Yan J; Yang J; Wang P; Liu Y; Wang X
Australas J Dermatol; 2024 May; 65(3):297-299. PubMed ID: 38450752
[No Abstract] [Full Text] [Related]
14. JAK1 inhibitor: A promising option for patients with pigmented purpuric dermatoses.
Cao S; Liu Y; Chen S; Zhao Q; Xue X; Huai P; Zhang F
J Eur Acad Dermatol Venereol; 2024 May; 38(5):e388-e390. PubMed ID: 37908169
[No Abstract] [Full Text] [Related]
15. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
[TBL] [Abstract][Full Text] [Related]
16. Excellent response to tofacitinib treatment in a patient with alopecia universalis.
Erduran F; Adışen E; Aksakal AB
Acta Dermatovenerol Alp Pannonica Adriat; 2017 Jun; 26(2):47-49. PubMed ID: 28632888
[TBL] [Abstract][Full Text] [Related]
17. JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
Boor PPC; de Ruiter PE; Asmawidjaja PS; Lubberts E; van der Laan LJW; Kwekkeboom J
Transl Res; 2017 Oct; 188():67-79. PubMed ID: 27931982
[TBL] [Abstract][Full Text] [Related]
18. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis.
Castelo-Soccio L
J Am Acad Dermatol; 2017 Apr; 76(4):754-755. PubMed ID: 28325392
[No Abstract] [Full Text] [Related]
19. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Smolen JS; Aletaha D; Gruben D; Zwillich SH; Krishnaswami S; Mebus C
Arthritis Rheumatol; 2017 Apr; 69(4):728-734. PubMed ID: 27907269
[TBL] [Abstract][Full Text] [Related]
20. Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
Lamba M; Hutmacher MM; Furst DE; Dikranian A; Dowty ME; Conrado D; Stock T; Nduaka C; Cook J; Krishnaswami S
Clin Pharmacol Ther; 2017 Jun; 101(6):745-753. PubMed ID: 27859030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
